Advertisement
BRKR vs TMO
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Bruker Corporation (BRKR) is a mid-cap life science tools maker with a market capitalization of roughly $9 billion, while Thermo Fisher Scientific (TMO) is a diversified science-and-services giant with annual revenue above $45 billion.
- Both stocks have delivered strong one-year gains, but TMO has shown steadier momentum recently, while BRKR carries a higher beta (a measure of volatility) and more mixed near-term earnings signals.
- BRKR faces margin pressure from helium input costs and soft U.S. academic and government demand; TMO is benefiting from improving pharma and biotech end markets.
- TMO holds a "Strong Buy" consensus from analysts, whereas BRKR holds a "Buy" consensus with a wider spread of target prices reflecting divided Street sentiment.
- The two companies differ sharply in scale, growth drivers, and diversification, making this a useful contrast for investors weighing quality and stability against a smaller, higher-beta turnaround story.
Introduction
This stock comparison examines two prominent names in life sciences and analytical instruments: Bruker Corporation (BRKR) and Thermo Fisher Scientific (TMO). Although they operate in adjacent markets, they represent very different investment profiles. BRKR is a focused, mid-cap provider of scientific instruments for life science research, diagnostics, and semiconductor metrology, while TMO is a diversified industry leader serving science across research, diagnostics, and biopharma services. Investors comparing these names may include growth-oriented traders evaluating relative performance, as well as long-term investors assessing market positioning, business-model quality, and resilience across the economic cycle.
BRKR Overview and Recent Performance
BRKR manufactures high-performance scientific instruments and analytical and diagnostic solutions, including segments focused on life science mass spectrometry (Bruker CALID), magnetic resonance (BioSpin), and nanoanalysis and semiconductor metrology (Bruker Nano). The company has leaned into post-genomic research, spatial biology, and next-generation semiconductor tools positioned for AI-driven demand.
In recent market activity, BRKR has posted strong share-price gains over the trailing year, but its momentum has been more uneven than its larger peer's. The company's latest quarterly results showed modest revenue growth alongside compressed margins, reflecting higher helium input costs and still-soft demand from U.S. academic and government customers. Analyst sentiment has been divided, with some firms raising price targets while others remain cautious on near-term execution and margin recovery. This mix of long-term growth appeal and nearer-term headwinds has kept BRKR's relative performance and market positioning volatile.
TMO Overview and Recent Performance
TMO is a diversified global leader serving science, spanning analytical instruments, laboratory products, specialty diagnostics, and pharmaceutical and biotech services through brands such as Thermo Scientific, Patheon, and PPD. With annual revenue exceeding $45 billion and a market capitalization around $250 billion, TMO is one of the largest companies in the life sciences tools sector.
Recent weeks have brought steady upward momentum for TMO, driven by improving pharma and biotech end markets, which represent a large share of its revenue. The company has reported sequential organic growth improvement and has raised its full-year guidance, supported by acquisitions such as Clario and a filtration and separation business from Solventum, while also divesting its microbiology unit. Analysts have responded by lifting price targets, with a consensus rating of "Strong Buy." This broad-based demand recovery and execution consistency have underpinned TMO's comparatively stable relative performance.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a much larger universe. Tickeron offers hundreds of AI trading bots that monitor thousands of different tickers, yet only those best suited to current market conditions earn a place in this curated section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and sets of tickers they trade, so no single approach fits every investor. By focusing on the most relevant, currently top-performing bots, the page helps users identify candidates aligned with shifting market environments. Explore the Trending AI Robots section to review the latest featured bots and their performance metrics.
Head-to-Head Comparison
The most immediate contrast is scale and diversification. TMO operates a broad, integrated portfolio that spans instruments, consumables, diagnostics, and outsourced pharma services, giving it multiple demand streams and a more defensive business model. BRKR is more concentrated in high-end instrumentation, which can amplify both upside in strong demand periods and downside when academic funding or capital spending slows.
Growth drivers also differ. TMO's recent momentum is tied to a recovery in pharma and biotech funding and to strategic acquisitions, while BRKR's story hinges on margin recovery from helium cost pressures, a rebound in U.S. academic spending, and longer-term exposure to AI-related semiconductor metrology. On risk factors, BRKR's smaller scale and higher beta (about 1.11) suggest greater price sensitivity, whereas TMO's beta near 0.93 and diversified revenue base indicate lower relative volatility. Market sentiment favors TMO's steadier execution, while BRKR offers a more contested, higher-upside turnaround profile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor TMO in the current environment. TMO's more consistent upward trend, improving end-market demand, diversified revenue base, and strong analyst consensus point to a steadier and more defensible setup. BRKR's stronger trailing-year percentage gains are accompanied by margin headwinds and mixed execution signals, which tend to reduce the probability of sustained, low-volatility momentum. In probabilistic terms, TMO currently presents a comparatively favorable risk-reward and trend profile, though BRKR's AI-linked growth levers could re-rate if its margin and demand recovery firm.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a Hold and TMO is a Hold.
BRKR in downward trend: 10-day moving average crossed below 50-day moving average on October 16, 2026
The 10-day moving average for BRKR crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BRKR as a result. In 69 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for BRKR turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 35 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
BRKR moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRKR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRKR advanced for three days, in 201 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
BRKR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.543) is normal, around the industry mean (2.908). P/E Ratio (-79.100) is within average values for comparable stocks, (2.616). Projected Growth (PEG Ratio) (1.070) is also within normal values, averaging (11.052). Dividend Yield (0.004) settles around the average of (0.009) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. BRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
TMO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for TMO turned positive on October 16, 2026. Looking at past instances where TMO's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on TMO as a result. In 54 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
Following a +5.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 196 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 145 of 246 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 20 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 21 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.768) is normal, around the industry mean (63.909). P/E Ratio (36.506) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
BRKR | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 77 | |
SMR RATING 1..100 | 92 | 60 | |
PRICE GROWTH RATING 1..100 | 45 | 21 | |
P/E GROWTH RATING 1..100 | 99 | 22 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (9) in the Medical Specialties industry is somewhat better than the same rating for TMO (68). This means that BRKR’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (77) in the Medical Specialties industry is in the same range as BRKR (100). This means that TMO’s stock grew similarly to BRKR’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as BRKR (92). This means that TMO’s stock grew similarly to BRKR’s over the last 12 months.
TMO's Price Growth Rating (21) in the Medical Specialties industry is in the same range as BRKR (45). This means that TMO’s stock grew similarly to BRKR’s over the last 12 months.
TMO's P/E Growth Rating (22) in the Medical Specialties industry is significantly better than the same rating for BRKR (99). This means that TMO’s stock grew significantly faster than BRKR’s over the last 12 months.
| BRKR | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 53% |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 61% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 68% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 62% |
| Advances ODDS (%) | 15 days ago 69% | 5 days ago 63% |
| Declines ODDS (%) | 6 days ago 74% | 1 day ago 62% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 65% |
| Aroon ODDS (%) | N/A | 1 day ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green while TMO’s FA Score has 2 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- BRKR’s TA Score: 3 bullish, 5 bearish.
- TMO’s TA Score: 4 bullish, 4 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а -1.56% price change this week, while TMO (@Medical Specialties) price change was +2.59% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.69%. For the same industry, the average monthly price growth was -10.46%, and the average quarterly price growth was -13.95%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.01%. For the same industry, the average monthly price growth was -7.30%, and the average quarterly price growth was +34.04%.
Reported Earning Dates
BRKR is expected to report earnings on Oct 29, 2026.
TMO is expected to report earnings on Oct 21, 2026.
Industries' Descriptions
@Medical/Nursing Services (-5.69% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-4.01% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EMXC | 93.31 | 1.04 | +1.13% |
| iShares MSCI Emerging Markets ex China ETF (EMXC) | |||
| TIME | 27.57 | 0.18 | +0.66% |
| Clockwise U.S. Core Equity ETF (TIME) | |||
| USEP | 42.11 | 0.06 | +0.14% |
| Innovator U.S. Equity Ultra Buffer ETF - September (USEP) | |||
| RISN | 30.39 | -0.04 | -0.12% |
| Inspire Capital Appreciation ETF (RISN) | |||
| AVRE | 44.60 | -0.42 | -0.93% |
| Avantis Real Estate ETF (AVRE) | |||
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with A. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then A could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | +1.04% | ||
| A - BRKR | 78% Closely correlated | -1.77% | ||
| MTD - BRKR | 75% Closely correlated | +0.21% | ||
| WAT - BRKR | 68% Closely correlated | -0.61% | ||
| RVTY - BRKR | 68% Closely correlated | -1.11% | ||
| TMO - BRKR | 66% Loosely correlated | -1.54% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | -1.54% | ||
| A - TMO | 74% Closely correlated | -1.77% | ||
| DHR - TMO | 71% Closely correlated | -2.01% | ||
| RVTY - TMO | 69% Closely correlated | -1.11% | ||
| IQV - TMO | 68% Closely correlated | -0.38% | ||
| BRKR - TMO | 67% Closely correlated | +1.04% | ||
More | ||||